Genkyotex

OverviewSuggest Edit

Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
TypePrivate
Founded2006
HQPlan-les-Ouates, CH
Websitegenkyotex.com

Latest Updates

Employees (est.) (Sept 2021)10(-9%)
Cybersecurity ratingAMore

Key People/Management at Genkyotex

Elias Papatheodorou

Elias Papatheodorou

CEO

Genkyotex Office Locations

Genkyotex has offices in Plan-les-Ouates and Archamps
Plan-les-Ouates, CH (HQ)
16 Chemin des Aulx
Archamps, FR
218 Avenue Marie Curie
Show all (2)

Genkyotex Financials and Metrics

Summary Metrics

Founding Date

2006

Genkyotex total Funding

$72.8 m

Genkyotex latest funding size

$21 m

Time since last funding

7 years ago

Genkyotex investors

Genkyotex's latest funding round in January 2015 was reported to be $21 m. In total, Genkyotex has raised $72.8 m
Show all financial metrics

Genkyotex Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Genkyotex Online and Social Media Presence

Embed Graph

Genkyotex News and Updates

Calliditas closes acquisition of a controlling interest in Genkyotex SA

STOCKHOLM, Nov. 3, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT) today announced the closing of the acquisition of 62.7% of Genkyotex SA ("Genkyotex") (Euronext Paris & Brussels: FR0013399474 - GKTX) in an off-market transaction....

Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA

STOCKHOLM, Aug. 13, 2020 /PRNewswire/ -- Transaction adds late-stage orphan pipeline asset and platform in inflammation and fibrosis. Calliditas to acquire 62.7% of Genkyotex for €20.3M in cash at €2.80 per share in an off-market transaction. Following the closing of the control...

Genkyotex Announces First Half 2019 Results

ARCHAMPS, France, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR00013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announces its consolidated financial results for the six months ended June 30, 2019, prepared in accordance with …

Genkyotex Conference Call for Post-Hoc Analysis of Setanaxib (GKT831) PBC Ph2 Trial and Business Update

ARCHAMPS, France, July 24, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, will hold a conference call on July 25, 2019 at 2pm CEST, following publication of the second quarter financial results. …

Genkyotex Invites Shareholders to Annual General Meeting on June 13, 2019

ARCHAMPS, France, May 23, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced it will hold its Annual General Meeting on June 13, 2019.

Genkyotex Reports Clinical Evidence of Anti-fibrotic Activity by GKT831 in Liver Fibrosis Patients

Top Line Efficacy Results from Phase 2 Primary Biliary Cholangitis (PBC) Trial
Show more

Genkyotex Blogs

Genkyotex’s setanaxib granted Orphan Drug Designation by the European Commission for the treatment of PBC

Genkyotex’s setanaxib granted Orphan Drug Designation by the European Commission for the treatment of PBC

Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex

Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex

Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC

Genkyotex’s setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC

Genkyotex announces the enrollment of the 1st patient in the Phase 2 trial of setanaxib in idiopathic pulmonary fibrosis (IPF)

Genkyotex announces the enrollment of the 1st patient in the Phase 2 trial of setanaxib in idiopathic pulmonary fibrosis (IPF)

Genkyotex announces agreement for Calliditas Therapeutics to acquire controlling interest in Genkyotex SA

Genkyotex announces agreement for Calliditas Therapeutics to acquire controlling interest in Genkyotex SA

Genkyotex announces the dosing of the first subjects in its Phase 1 study with high-dose setanaxib

Genkyotex announces the dosing of the first subjects in its Phase 1 study with high-dose setanaxib
Show more

Genkyotex Frequently Asked Questions

  • When was Genkyotex founded?

    Genkyotex was founded in 2006.

  • Who are Genkyotex key executives?

    Genkyotex's key executives are Elias Papatheodorou.

  • How many employees does Genkyotex have?

    Genkyotex has 10 employees.

  • Who are Genkyotex competitors?

    Competitors of Genkyotex include QGel, ReViral and CG Oncology.

  • Where is Genkyotex headquarters?

    Genkyotex headquarters is located at 16 Chemin des Aulx, Plan-les-Ouates.

  • Where are Genkyotex offices?

    Genkyotex has offices in Plan-les-Ouates and Archamps.

  • How many offices does Genkyotex have?

    Genkyotex has 2 offices.